Table 1 Subject characteristics according to progression and amyloid status

Number of subjects

154 (56)

122 (44)

93 (80)

23 (20)

61 (38)

99 (62)

Age (years)

65.5 ± 7.7

68.3 ± 8.1*

63.8 ± 7.9

68.2 ± 8.7^†

68.2 ± 6.5

68.3 ± 8.0

Male gender

97 (63)

67 (56)

64 (69)

16 (70)

33 (54)

51 (51)

Education

5.0 ± 1.5

4.9 ± 1.7

4.8 ± 1.7

5.0 ± 1.6

5.3 ± 1.2

4.9 ± 1.7

MMSE

27.0 ± 2.2

26.1 ± 2.6*

27.0 ± 2.2

26.6 ± 2.5

27.0 ± 2.2

26.0 ± 2.6^†

CSF Aβ_1–42

794 ± 307

534 ± 194*

999 ± 207

848 ± 172*

481 ± 104

462 ± 107

WMH (Fazekas)

0.99 ± 0.92

1.03 ± 0.80

0.88 ± 0.93

1.30 ± 1.02

1.15 ± 0.89

0.97 ± 0.73

NGMV

0.41 ± 0.04

0.39 ± 0.05*

0.42 ± 0.04

0.39 ± 0.06*

0.41 ± 0.04

0.39 ± 0.04^†

Follow-up (years)

2.5 ± 1.5

2.6 ± 1.7

2.3 ± 1.4

2.8 ± 2.0

2.7 ± 1.7

2.6 ± 1.3

 AD

–

104 (85)

–

10 (43)

–

94 (95)

 DLB

–

3 (2)

–

2 (9)

–

1 (1)

 FTD

–

4 (3)

–

3 (13)

–

1 (1)

 VaD and mixed

–

9 (7)

–

6 (26)

–

3 (3)

 Other

–

2 (2)

–

2 (9)

–

0 (0)